Biotech stocks have been a hot topic in the investment world for several years now. With advancements in technology and an increased focus on healthcare, the biotech industry has experienced significant growth and innovation. As a result, many investors are turning to biotech stocks as a way to diversify their portfolio and potentially earn significant returns.
Here are three “Strong Buy” Biotech stocks from Wall Street –
Biogen Inc. – SYM: BIIB
Recent Price: $243.89
Price Target: $309.64
Firms with Buy Rating: Jefferies, Goldman Sachs, Morgan Stanley
Description: Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
The Battery Metal Nobody Told You About
According to McKinsey and Company, the battery storage market is growing rapidly, especially with the transition to clean, renewable energy.
Lithium-ion batteries still grab most of the headlines. But analysts now call safe and long-lasting batteries made with vanadium “the future of battery tech.”
See why investors are taking a hard look at vanadium right now.
Immunovant, Inc. – SYM: IMVT
Recent Price: $41.17
Price Target: $51.60
Firms with Buy Rating: Piper Sandler, UBS, Stifel Nicolaus
Description: Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
The “Inception” Revolution Is Here!
A mind-blowing new technology (not AI) is set to create the largest economic disruption since 1908. And while you won’t see anything about it on the news… Microsoft, Intel, and Google are all quietly piling BILLIONS into this tiny tech behind the scenes… Even Bill Gates went on the record saying Inception will be “… as revolutionary as the personal computer, the Internet, and the mobile phone.”
Click here for the full story.
DexCom, Inc. – SYM: DXCM
Recent Price: $124.50
Price Target: $138.62
Firms with Buy Rating: Wells Fargo, Jefferies, Piper Sandler
Description: DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Find out how owning physical gold now could hedge your savings against economic uncertainty.
Get FREE Access Now